科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300858 科拓生物

交易中 12-22 11:14:42

{"stockData":{"symbol":"300858","market":"SZ","secType":"STK","nameCN":"科拓生物","latestPrice":16.78,"timestamp":1766373282000,"preClose":16.79,"halted":0,"volume":1850750,"delay":0,"changeRate":-0.0006,"floatShares":194000000,"shares":263000000,"eps":0.3773,"marketStatus":"交易中","change":-0.01,"latestTime":"12-22 11:14:42","open":16.77,"high":16.9,"low":16.66,"amount":31013500,"amplitude":0.0143,"askPrice":16.79,"askSize":50,"bidPrice":16.78,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.3773,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1766374200000},"marketStatusCode":2,"adr":0,"adjPreClose":16.79,"symbolType":"stock","openAndCloseTimeList":[[1766367000000,1766374200000],[1766379600000,1766386800000]],"highLimit":18.47,"lowLimit":15.11,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":263495118,"isCdr":false,"pbRate":2.42,"roa":"--","peRate":44.473893,"roe":"4.2%","epsLYR":0.36,"committee":0.154472,"marketValue":4421000000,"turnoverRate":0.0096,"status":1,"floatMarketCap":3251000000},"requestUrl":"/m/hq/s/300858","defaultTab":"news","newsList":[{"id":"2592270904","title":"科拓生物（300858）披露5%以上股东减持股份触及1%整数倍，12月18日股价上涨0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592270904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592270904?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:21","pubTimestamp":1766067692,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，科拓生物报收于16.42元，较前一交易日上涨0.37%，最新总市值为43.27亿元。该股当日开盘16.4元，最高16.67元，最低16.29元，成交额达4717.29万元，换手率为1.48%。减持后，其持股数量由23,714,466股减少至21,079,566股，持股比例由9.0000%下降至8.0000%。本次减持系履行此前披露的减持计划，未违反相关承诺，减持计划尚未实施完毕。本次权益变动不导致公司控股股东或实际控制人发生变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800038667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2592995614","title":"12月17日科拓生物现2笔折价15.04%的大宗交易 合计成交1973.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995614","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592995614?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:43","pubTimestamp":1765964595,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日科拓生物发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交1.42万手，折价成交2笔。该股近期无解禁股上市。截至2025年12月17日收盘，科拓生物(300858)报收于16.36元，下跌1.09%，换手率2.16%，成交量4.19万手，成交额6869.96万元。该股近半年内有股东持股变动，合计净减持21.15万股，股东增减持明细如下表：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700027786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2590516548","title":"科拓生物：12月10日高管乔向前减持股份合计6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516548","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590516548?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:03","pubTimestamp":1765458202,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月11日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年12月10日公司董事,高管乔向前共减持公司股份6.0万股，占公司总股本为0.0228%。变动期间公司股价下跌0.94%，12月10日当日收盘报16.95元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2590349533","title":"科拓生物：12月8日高管乔向前减持股份合计2.07万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349533","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590349533?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:03","pubTimestamp":1765285415,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月9日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年12月8日公司董事,高管乔向前共减持公司股份2.07万股，占公司总股本为0.0079%。变动期间公司股价下跌1.27%，12月8日当日收盘报17.16元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900037883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2589353444","title":"科拓生物：12月5日高管乔向前减持股份合计15.13万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353444","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589353444?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765199006,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月8日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年12月5日公司董事,高管乔向前共减持公司股份15.13万股，占公司总股本为0.0574%。变动期间公司股价下跌0.57%，12月5日当日收盘报17.38元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800032149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2588006550","title":"科拓生物：内蒙古呼和浩特食品工厂生产运营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2588006550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588006550?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:06","pubTimestamp":1764831979,"startTime":"0","endTime":"0","summary":"证券之星消息，科拓生物(300858)12月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司内蒙古基地全面投产了吗科拓生物回复：尊敬的投资者您好，内蒙古呼和浩特食品工厂生产运营正常，正根据订单需求有序分批释放产能。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400017793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2588804951","title":"科拓生物：12月2日高管乔向前减持股份合计35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588804951","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588804951?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:02","pubTimestamp":1764766974,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月3日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年12月2日公司董事,高管乔向前共减持公司股份35.0万股，占公司总股本为0.1328%。变动期间公司股价上涨0.22%，12月2日当日收盘报18.02元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2588720901","title":"科拓生物：11月28日高管乔向前减持股份合计17.61万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720901","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588720901?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:03","pubTimestamp":1764594181,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月1日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年11月28日公司董事,高管乔向前共减持公司股份17.61万股，占公司总股本为0.0668%。变动期间公司股价上涨1.4%，11月28日当日收盘报18.16元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100033849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2586787326","title":"科拓生物：11月27日高管乔向前减持股份合计5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586787326","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586787326?lang=zh_cn&edition=full","pubTime":"2025-11-28 21:02","pubTimestamp":1764334966,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月28日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年11月27日公司董事,高管乔向前共减持公司股份5.0万股，占公司总股本为0.019%。变动期间公司股价下跌0.44%，11月27日当日收盘报17.91元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800036778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2586228312","title":"科拓生物：11月26日高管乔向前减持股份合计33.32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586228312","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586228312?lang=zh_cn&edition=full","pubTime":"2025-11-27 21:02","pubTimestamp":1764248543,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月27日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年11月26日公司董事,高管乔向前共减持公司股份33.32万股，占公司总股本为0.1265%。变动期间公司股价下跌3.07%，11月26日当日收盘报17.99元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700035997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2586272473","title":"科拓生物：11月24日高管乔向前减持股份合计23.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586272473","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586272473?lang=zh_cn&edition=full","pubTime":"2025-11-25 21:02","pubTimestamp":1764075779,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月25日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年11月24日公司董事,高管乔向前共减持公司股份23.03万股，占公司总股本为0.0874%。变动期间公司股价上涨1.1%，11月24日当日收盘报18.37元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2584057386","title":"科拓生物：主营业务为食用益生菌制品研发生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2584057386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584057386?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:39","pubTimestamp":1763426349,"startTime":"0","endTime":"0","summary":"证券之星消息，科拓生物11月17日在投资者关系平台上答复投资者关心的问题。同时，公司已先期布局制药领域，正与深圳未知君生物科技有限公司等合作推进益生菌新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800006106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2584625683","title":"科拓生物：11月14日高管乔向前减持股份合计15.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625683","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584625683?lang=zh_cn&edition=full","pubTime":"2025-11-17 21:03","pubTimestamp":1763384625,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月17日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年11月14日公司董事,高管乔向前共减持公司股份15.95万股，占公司总股本为0.0605%。变动期间公司股价上涨3.75%，11月14日当日收盘报19.9元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700034080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2583983035","title":"科拓生物：11月12日高管乔向前减持股份合计15.64万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583983035","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583983035?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:03","pubTimestamp":1763039004,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月13日市场公开信息、上市公司公告及交易所披露数据整理，科拓生物（300858）最新董监高及相关人员股份变动情况：2025年11月12日公司董事,高管乔向前共减持公司股份15.64万股，占公司总股本为0.0594%。变动期间公司股价上涨7.04%，11月12日当日收盘报19.17元。科拓生物近半年内的董监高及核心技术人员增减持详情如下：科拓生物的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300040374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2582932506","title":"11月12日科拓生物涨7.04%，工银新生代消费混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582932506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582932506?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:33","pubTimestamp":1762936382,"startTime":"0","endTime":"0","summary":"证券之星消息，11月12日科拓生物涨7.04%，收盘报19.17元，换手率10.75%，成交量20.82万手，成交额3.93亿元。重仓科拓生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为工银瑞信基金的工银新生代消费混合。该公募基金现任基金经理为林梦。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200025757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2577597715","title":"科拓生物：已与茶颜悦色达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2577597715","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577597715?lang=zh_cn&edition=full","pubTime":"2025-10-24 09:07","pubTimestamp":1761268023,"startTime":"0","endTime":"0","summary":"证券之星消息，科拓生物(300858)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：在全民运动，大健康的环境下，公司有无凭借自身优势和头部饮品企业合作。比如奶茶等科拓生物回复：尊敬的投资者您好，公司依托在益生菌领域深厚的研发积累与技术应用优势，已与茶颜悦色达成合作，与其他奶茶品牌的合作也在有序推进中。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2577559799","title":"科拓生物：KEX02活菌胶囊联合PD-1抑制剂治疗非小细胞肺癌处于Ⅰ期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2577559799","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577559799?lang=zh_cn&edition=full","pubTime":"2025-10-24 09:06","pubTimestamp":1761268016,"startTime":"0","endTime":"0","summary":"证券之星消息，科拓生物(300858)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：关于子公司君拓生物的肠道微生态创新药物管线‌进展如何，联合PD-1抑制剂治疗非小细胞肺癌实验进展如何？科拓生物回复：尊敬的投资者您好，公司与深圳未知君生物科技有限公司正在有序推进关于KEX02活菌胶囊联合PD-1抑制剂治疗非小细胞肺癌的药物管线临床研究，项目目前处于Ⅰ期临床阶段。公司会根据进展情况及时进行信息披露。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2577559705","title":"科拓生物：子公司获食品生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2577559705","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577559705?lang=zh_cn&edition=full","pubTime":"2025-10-24 09:06","pubTimestamp":1761268014,"startTime":"0","endTime":"0","summary":"证券之星消息，科拓生物10月23日在投资者关系平台上答复投资者关心的问题。公司将根据客户订单情况有序分批投产，逐步释放产能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2577791559","title":"科拓生物：公司未参与未知君菌株研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2577791559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577791559?lang=zh_cn&edition=full","pubTime":"2025-10-24 09:06","pubTimestamp":1761268011,"startTime":"0","endTime":"0","summary":"证券之星消息，科拓生物(300858)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否参与了未知君创新性开发，未知君分离并开发的菌株XA-511（Megasphaera indica），正式获得国家专利授权，专利名称为《巨球形菌属细菌在制备治疗癌症的药物中的应用》，专利编号为ZL 202310941665.1。科拓生物回复：尊敬的投资者您好，公司未参与该项目的研发或合作。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2577310378","title":"科拓生物（300858）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2577310378","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577310378?lang=zh_cn&edition=full","pubTime":"2025-10-23 06:05","pubTimestamp":1761170725,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期科拓生物发布2025年三季报。根据财报显示，科拓生物营收净利润同比双双增长。截至本报告期末，公司营业总收入2.67亿元，同比上升22.25%，归母净利润7623.2万元，同比上升7.08%。按单季度数据看，第三季度营业总收入1.04亿元，同比上升28.98%，第三季度归母净利润3502.69万元，同比上升26.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300004148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766373316164,"stockEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.1074},{"period":"3month","weight":-0.082},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.072},{"period":"ytd","weight":0.1778}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京科拓恒通生物技术股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"17081人(较上一季度增加5.63%)","perCapita":"11343股","listingDate":"2020-07-27","address":"北京市怀柔区雁栖经济开发区牤牛河路31号院1号-2","registeredCapital":"26349万元","survey":"　　北京科拓恒通生物技术股份有限公司的主营业务是食用益生菌制品、动植物微生态制剂以及复配食品添加剂研发、生产与销售。公司的主要产品是食用益生菌制品、动植物微生态制剂以及复配食品添加剂。公司主导并参与制定的团体标准《益生菌食品》T/CNFIA131-2021、《益生菌制品乳酸菌类后生元》T/CBFIA09001-2023，分别于2021年11月8日、2023年1月9日发布。公司参与制定的国家标准《食品加工用菌种制剂生产卫生规范》GB31612-2023、《食品加工用菌种制剂》GB31639-2023，于2023年9月6日发布，《食品生产追溯体系通用技术规范》GB/T45547-2025，于2025年4月25日发布。公司参与制定的行业标准《食品用菌种制剂》QB/T4575-2023，于2023年12月20日发布。公司参与制定的团体标准《植物蛋白饮料植物酸奶》T/WSJD12-2020、《食品用益生菌通则》T/CIFST009-2022、《晶球益生菌》T/CIET253-2023、《食品用菌种检验鼠李糖乳酪杆菌检验PMA-qPCR法》T/CIFST020-2024、《益生菌制剂食品》T/CHC1014—2024，分别于2020年12月16日、2022年6月16日、2023年10月25日、2024年4月1日、2024年8月23日发布。公司将充分发挥自身技术优势，助力行业健康规范高质量发展。公司参与的《优良乳酸菌种质资源挖掘与产业化关键技术创制及应用》项目，荣获2023年度国家科学技术进步奖二等奖。该项目攻克了乳酸菌代谢调控培养和细胞损伤靶向保护工程技术，突破了高活性乳酸菌产业化卡脖子难题、创制了菌株高效互作和精准配伍关键技术，打破了国外菌株、技术和产品的垄断，引领我国乳酸菌产业科技进步和高质量发展。","listedPrice":23.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科拓生物(300858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科拓生物,300858,科拓生物股票,科拓生物股票老虎,科拓生物股票老虎国际,科拓生物行情,科拓生物股票行情,科拓生物股价,科拓生物股市,科拓生物股票价格,科拓生物股票交易,科拓生物股票购买,科拓生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科拓生物(300858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}